OncoPrecision is a technology company.
OncoPrecision has raised $3.9M across 2 funding rounds.
OncoPrecision has raised $3.9M in total across 2 funding rounds.
OncoPrecision has raised $3.9M in total across 2 funding rounds.
OncoPrecision's investors include 7percent Ventures, Creative Ventures, Left Lane Capital, Race Capital, Sapphire Ventures, SOSV, Swift Ventures, The House Fund, Victor Jacobsson, Learn Capital, Twenty Seven Ventures.
OncoPrecision is a biotechnology company founded in 2020 that develops high-throughput platforms combining patient-derived tumor models, engineered cells, and AI to predict cancer patients' responses to therapies and advance a pipeline of therapeutic antibodies.[1][2][3] It serves cancer patients, physicians, and pharmaceutical partners by replicating the tumor microenvironment ex vivo through miniaturized "Patient Micro Avatars," enabling rapid screening of single and combination drugs with single-cell resolution analysis via flow cytometry and machine learning.[1][2] This solves the problem of cancer's heterogeneity by shifting from one-size-fits-all treatments to personalized predictions, with applications in precision oncology services and novel antibody development targeting high unmet needs like tumor-associated macrophages in multiple myeloma.[1][3] The company has raised approximately $3.3M–$4.2M in seed funding, employs 11–50 people, and operates from Córdoba, Argentina, with growing clinical partnerships across North and South America.[1][2]
OncoPrecision spun out from Dr. Gastón Soria's Synthetic Lethality in Cancer Lab at the University of Córdoba, where his team developed high-throughput screening for target identification and drug discovery in collaborations with major pharmaceutical companies.[1][3] Dr. Soria recognized the potential of patient-derived models to treat each cancer case as a unique disease, prompting the company's formation in 2020 alongside Co-Founder & CEO Tarek Zaki.[1] Early traction came from validating a triple co-culture method that boosts patient-derived cancer cell viability 60x in a 2.5D format, outperforming sequencing or organoid approaches, with real patient data confirming predictive accuracy in under 10 days.[2] This pivot aligned with the need for bespoke treatments, as Zaki noted the industry's shift toward patient-tailored cancer care.[1]
OncoPrecision rides the precision oncology wave, where AI and patient-derived models address translational failures in drug discovery by prioritizing patient-centric data from the start.[1][3] Timing is ideal amid advances in single-cell analysis and high-throughput screening, fueled by market forces like rising cancer incidence, demand for personalized medicine, and pharma's push for higher success rates in antibody therapeutics.[1][2][3] It influences the ecosystem by partnering with clinical centers and pharma to validate platforms, accelerating deployment of predictive tools and novel programs in immunity, inflammation, and hard-to-treat cancers like multiple myeloma.[3]
OncoPrecision is poised to expand its antibody pipeline with ONC001 advancing to development candidate stage, leveraging clinical partnerships for broader validation and pharma co-development.[3] Trends like AI-enhanced phenotypic screening and ex vivo avatars will shape its growth, potentially scaling to more indications and modalities amid biotech's focus on patient-first discovery.[1][3] Its influence may evolve from precision diagnostics to a key platform player, driving higher clinical success rates and tying back to its core mission: making drug discovery start with patients for transformative cancer outcomes.[3]
OncoPrecision has raised $3.9M across 2 funding rounds. Most recently, it raised $3.0M Seed in July 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2022 | $3.0M Seed | 7percent Ventures, Creative Ventures, Left Lane Capital, Race Capital, Sapphire Ventures, SOSV, Swift Ventures, The House Fund, Victor Jacobsson | |
| Feb 1, 2020 | $850K Seed | Learn Capital, SOSV, Twenty Seven Ventures |